Insight Molecular Diagnostics Q3 revenue beats, net loss narrows on cost cuts
IMDX•Insight Molecular Diagnostics reported Q3 revenue of $559,000, beating the $244,200 analyst consensus, while net loss narrowed to $3.58 million as operating expenses declined. The company expects to submit an FDA response for GraftAssureDx before the January 21, 2027 deadline.
1. Q3 results
Q3 revenue rose to $559,000, above the $244,200 consensus estimate from five analysts. Net loss was $3.58 million and narrowed from a year earlier as operating and research and development expenses declined sequentially.
2. FDA review and outlook
The company expects to submit its FDA response for GraftAssureDx before the January 21, 2027 deadline. The review clock is expected to restart upon submission, with about half of the 150-day review remaining. The company continues to target outgoing free cash flow of about $8 million in Q4 2026.




